ProFunds Biotechnology UltraSector Svc
Profunds3435 Stelzler RdColumbus, OH 43219
Map
Phone: 888-776-3637
| Category: | Health | | Fund Family: | ProFunds | | Net Assets: | 167.68M | | Year-to-Date Return: | 37.06% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | Jun 18, 2000 |
|
Hratch Najarian
Lead Manager since Sep 30, 2011 | | | Najarian has been an associate portfolio manager with ProFund Advisors since 2004. Previously, he worked as a portfolio analyst for ProFund Advisors from 2003 to 2004, junior analyst from 2002 to 2003 and institutional client services representative from 2000 to 2002. |
| Min Initial Investment: | 15,000 | | Min Initial Investment, IRA: | 15,000 | | Min Initial Investment, AIP: | 15,000 | | Min Subsequent Investment: | N/A | | Min Subsequent Investment, IRA: | N/A | | Min Subsequent Investment, AIP: | N/A |
|
| |
| The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. BiotechnologySM Index.
The fund invests in securities and derivatives that the adviser believes, in combination, should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the biotechnology sector of the U.S. equity market. It is non-diversified. |
| Last Dividend
:
| N/A | | Last Cap Gain
:
| N/A | | Annual Holdings Turnover
(Oct 5, 2010)
:
| 37.00% | | Average for Category: | 62.51% |
|
| Expense | BIPSX | Category Avg |
|---|
| Annual Report Expense Ratio (net): | 2.73% | 1.52% | | Prospectus Net Expense Ratio: | 2.78% | N/A | | Prospectus Gross Expense Ratio: | 3.00% | N/A | | Max 12b1 Fee: | 1.00% | N/A | | Max Front End Sales Load: | N/A | 5.28% | | Max Deferred Sales Load:
| N/A | 2.66% | | 3 Yr Expense Projection*: | 907 | 646 | | 5 Yr Expense Projection*: | 1,558 | 1,000 | | 10 Yr Expense Projection*: | 3,302 | 1,969 |
|
|
2.31(1.73%) May 2